Advances in Hereditary Colorectal and Pancreatic Cancers

Clinical Therapeutics

Volumn 38, Issue 7, 2016, Pages 1600-1621

  Underhill, Meghan L ^a,b   Germansky, Katharine A ^c   Yurgelun, Matthew B ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

familial gastrointestinal cancer; genetic testing; Lynch syndrome; multigene panel testing

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

CANCER GENETICS; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; COLORECTAL CANCER; COWDEN SYNDROME; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GARDNER SYNDROME; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY PANCREATIC CANCER; HUMAN; MUIR TORRE SYNDROME; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; REVIEW; SOCIAL PSYCHOLOGY; TUMOR GENE; TURCOT SYNDROME; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETICS; PANCREATIC NEOPLASMS; RISK;

COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC TESTING; HUMANS; PANCREATIC NEOPLASMS; RISK;

EID: 84961875813     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.03.017     Document Type: Review

References (150)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. 2 Lynch, H.T., de la Chapelle, A., Hereditary colorectal cancer. N Engl J Med 348 (2003), 919–932.
3. 3 Yurgelun, M.B., Next-generation strategies for hereditary colorectal cancer risk assessment. J Clin Oncol 33 (2015), 388–393.
4. 4 Giardiello, F.M., Allen, J.I., Axilbund, J.E., et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147 (2014), 502–526.
5. 5 Ligtenberg, M.J., Kuiper, R.P., Chan, T.L., et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 41 (2009), 112–117.
6. 6 Hampel, H., Frankel, W., Panescu, J., et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66 (2006), 7810–7817.
7. 7 Jarvinen, H.J., Aarnio, M., Mustonen, H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000), 829–834.
8. 8 Burn, J., Gerdes, A.M., Macrae, F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378 (2011), 2081–2087.
9. 9 Schmeler, K.M., Lynch, H.T., Chen, L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006), 261–269.
10. 10 Vasen, H.F., Mecklin, J.P., Khan, P.M., et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991), 424–425.
11. 11 Umar, A., Boland, C.R., Terdiman, J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004), 261–268.
12. 12 Grover, S., Stoffel, E.M., Bussone, L., et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2 (2004), 813–819.
13. 13 Syngal, S., Brand, R.E., Church, J.M., et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. quiz 263 Am J Gastroenterol 110 (2015), 223–262.
14. 14 NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed March 5, 2016.
15. 15 Hampel, H., Frankel, W.L., Martin, E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26 (2008), 5783–5788.
16. 16 Hampel, H., Frankel, W.L., Martin, E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352 (2005), 1851–1860.
17. 17 Moreira, L., Balaguer, F., Lindor, N., et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308 (2012), 1555–1565.
18. 18 Heald, B., Plesec, T., Liu, X., et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 31 (2013), 1336–1340.
19. 19 Ladabaum, U., Wang, G., Terdiman, J., et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155 (2011), 69–79.
20. 20 Ward, R.L., Hicks, S., Hawkins, N.J., Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 31 (2013), 2554–2562.
21. 21 Egoavil, C., Alenda, C., Castillejo, A., et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One, 8, 2013, e79737.
22. 22 Ferguson, S.E., Aronson, M., Pollett, A., et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120 (2014), 3932–3939.
23. 23 Goodfellow, P.J., Billingsley, C.C., Lankes, H.A., et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33 (2015), 4301–4308.
24. 24 Yurgelun, M.B., Goel, A., Hornick, J.L., et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) 5 (2012), 574–582.
25. 25 Everett, J.N., Raymond, V.M., Dandapani, M., et al. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150 (2014), 1315–1321.
26. 26 Lamba, A.R., Moore, A.Y., Moore, T., et al. Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome. Fam Cancer 14 (2015), 259–264.
27. 27 Aparicio, T., Svrcek, M., Zaanan, A., et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 109 (2013), 3057–3066.
28. 28 Williams, A.S., Huang, W.Y., The analysis of microsatellite instability in extracolonic gastrointestinal malignancy. Pathology 45 (2013), 540–552.
29. 29 Win, A.K., Macinnis, R.J., Dowty, J.G., et al. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet 50 (2013), 785–793.
30. 30 Kastrinos, F., Ojha, R.P., Leenen, C., et al. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. J Natl Cancer Inst, 108, 2016.
31. 31 Chen, S., Wang, W., Lee, S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296 (2006), 1479–1487.
32. 32 Kastrinos, F., Steyerberg, E.W., Mercado, R., et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140 (2011), 73–81.
33. 33 Khan, O., Blanco, A., Conrad, P., et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol 106 (2011), 1822–1827 quiz 1828.
34. 34 Dinh, T.A., Rosner, B.I., Atwood, J.C., et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4 (2011), 9–22.
35. 35 Mercado, R.C., Hampel, H., Kastrinos, F., et al. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 14 (2012), 670–680.
36. 36 Lee, S.Y., Kim, D.W., Shin, Y.K., et al. Validation of Prediction Models for Mismatch Repair Gene Mutations in Koreans. Cancer Res Treat, 2015 [Epub ahead of print].
37. 37 Yurgelun, M.B., Allen, B., Kaldate, R.R., et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology, 149(604-13), 2015, e20.
38. 38 Domchek, S.M., Bradbury, A., Garber, J.E., et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. J Clin Oncol 31 (2013), 1267–1270.
39. 39 Hall, M.J., Forman, A.D., Pilarski, R., et al. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 12 (2014), 1339–1346.
40. 40 Robson, M., Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. J Clin Oncol 32 (2014), 1987–1989.
41. 41 Cragun, D., Radford, C., Dolinsky, J.S., et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 86 (2014), 510–520.
42. 42 Chubb, D., Broderick, P., Frampton, M., et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol 33 (2015), 426–432.
43. 43 Robson, M.E., Bradbury, A.R., Arun, B., et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33 (2015), 3660–3667.
44. 44 Struewing, J.P., Hartge, P., Wacholder, S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997), 1401–1408.
45. 45 Roa, B.B., Boyd, A.A., Volcik, K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (1996), 185–187.
46. 46 Metcalfe, K.A., Poll, A., Royer, R., et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28 (2010), 387–391.
47. 47 McClain, M.R., Palomaki, G.E., Nathanson, K.L., et al. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 7 (2005), 28–33.
48. 48 Garber, J.E., Syngal, S., One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers. J Natl Cancer Inst 96 (2004), 2–3.
49. 49 Mersch, J., Jackson, M.A., Park, M., et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121 (2015), 269–275.
50. 50 Kirchhoff, T., Satagopan, J.M., Kauff, N.D., et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96 (2004), 68–70.
51. 51 Phelan, C.M., Iqbal, J., Lynch, H.T., et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer 110 (2014), 530–534.
52. 52 Croitoru, M.E., Cleary, S.P., Di Nicola, N., et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96 (2004), 1631–1634.
53. 53 Jenkins, M.A., Croitoru, M.E., Monga, N., et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15 (2006), 312–314.
54. 54 Nieuwenhuis, M.H., Vogt, S., Jones, N., et al. Evidence for accelerated colorectal adenoma–carcinoma progression in MUTYH-associated polyposis?. Gut 61 (2012), 734–738.
55. 55 Casper, M., Plotz, G., Juengling, B., et al. MUTYH hotspot mutations in unselected colonoscopy patients. Colorectal Dis 14 (2012), e238–e244.
56. 56 Win, A.K., Cleary, S.P., Dowty, J.G., et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 129 (2011), 2256–2262.
57. 57 Win, A.K., Dowty, J.G., Cleary, S.P., et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology, 146, 2014 1208–11.e1–5.
58. 58 Jones, N., Vogt, S., Nielsen, M., et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137 (2009), 489–494 494.e1; quiz 725–6.
59. 59 Lubbe, S.J., Di Bernardo, M.C., Chandler, I.P., et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 27 (2009), 3975–3980.
60. 60 Peterlongo, P., Mitra, N., Chuai, S., et al. Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. Int J Cancer 114 (2005), 505–507.
61. 61 Balaguer, F., Castellvi-Bel, S., Castells, A., et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 5 (2007), 379–387.
62. 62 Malkin, D., Li-fraumeni syndrome. Genes Cancer 2 (2011), 475–484.
63. 63 Kamihara, J., Rana, H.Q., Garber, J.E., Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35 (2014), 654–662.
64. 64 Wong, P., Verselis, S.J., Garber, J.E., et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130 (2006), 73–79.
65. 65 Yurgelun, M.B., Masciari, S., Joshi, V.A., et al. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol 1 (2015), 214–221.
66. 66 Garber, J.E., Goldstein, A.M., Kantor, A.F., et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51 (1991), 6094–6097.
67. 67 Gonzalez, K.D., Noltner, K.A., Buzin, C.H., et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27 (2009), 1250–1256.
68. 68 Li, F.P., Fraumeni, J.F. Jr., Mulvihill, J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 48 (1988), 5358–5362.
69. 69 Tinat, J., Bougeard, G., Baert-Desurmont, S., et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27 (2009), e108–e109 author reply e110.
70. 70 NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2016. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed March 5, 2016.
71. 71 Lindor, N.M., Rabe, K., Petersen, G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293 (2005), 1979–1985.
72. 72 Palles, C., Cazier, J.B., Howarth, K.M., et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45 (2013), 136–144.
73. 73 Elsayed, F.A., Kets, C.M., Ruano, D., et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet 23 (2015), 1080–1084.
74. 74 Bellido, F., Pineda, M., Aiza, G., et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med, 2015 [E-pub ahead of print].
75. 75 Valle, L., Hernandez-Illan, E., Bellido, F., et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 23 (2014), 3506–3512.
76. 76 Jansen, A.M., van Wezel, T., van den Akker, B.E., et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet, 2015 [Epub ahead of print].
77. 77 Spier, I., Holzapfel, S., Altmuller, J., et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 137 (2015), 320–331.
78. 78 Nieminen, T.T., O'Donohue, M.F., Wu, Y., et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology, 147, 2014 595–598.e5.
79. 79 Kessel, R., Vlachos, A., Lipton, J.M., Ribosomopathy association with colorectal cancer. Gastroenterology, 148, 2015, 258.
80. 80 Segui, N., Mina, L.B., Lazaro, C., et al. Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair. Gastroenterology 149 (2015), 563–566.
81. 81 Jaeger, E., Leedham, S., Lewis, A., et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 44 (2012), 699–703.
82. 82 Weren, R.D., Ligtenberg, M.J., Kets, C.M., et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47 (2015), 668–671.
83. 83 Rivera, B., Castellsague, E., Bah, I., et al. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N Engl J Med 373 (2015), 1985–1986.
84. 84 Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003), 247–257.
85. 85 Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28 (2010), 3219–3226.
86. 86 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 (2015), 2509–2520.
87. 87 Movahedi, M., Bishop, D.T., Macrae, F., et al. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. J Clin Oncol 33 (2015), 3591–3597.
88. 88 Grover, S., Syngal, S., Hereditary pancreatic cancer. Gastroenterology 139 (2010), 1076–1080 1080.e1–2.
89. 89 Kastrinos, F., Mukherjee, B., Tayob, N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302 (2009), 1790–1795.
90. 90 Korsse, S.E., Harinck, F., van Lier, M.G., et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 50 (2013), 59–64.
91. 91 Vasen, H.F., Gruis, N.A., Frants, R.R., et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87 (2000), 809–811.
92. 92 Rebours, V., Boutron-Ruault, M.C., Schnee, M., et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 103 (2008), 111–119.
93. 93 Jones, S., Hruban, R.H., Kamiyama, M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324, 2009, 217.
94. 94 Roberts, N.J., Jiao, Y., Yu, J., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2 (2012), 41–46.
95. 95 Ruijs, M.W., Verhoef, S., Rookus, M.A., et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47 (2010), 421–428.
96. 96 Whitcomb, D.C., Shelton, C.A., Brand, R.E., Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology, 149, 2015 1252-1264.e4.
97. 97 Wang, W., Chen, S., Brune, K.A., et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 25 (2007), 1417–1422.
98. 98 Holter, S., Borgida, A., Dodd, A., et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol 33 (2015), 3124–3129.
99. 99 Grant, R.C., Selander, I., Connor, A.A., et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148 (2015), 556–564.
100. 100 Salo-Mullen, E.E., O'Reilly, E.M., Kelsen, D.P., et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer 121 (2015), 4382–4388.
101. 101 Fogelman, D., Sugar, E.A., Oliver, G., et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76 (2015), 489–498.
102. 102 Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33 (2015), 244–250.
103. 103 Carnevale, J., Ashworth, A., Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. J Clin Oncol 33 (2015), 3080–3081.
104. 104 Canto, M.I., Hruban, R.H., Fishman, E.K., et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142 (2012), 796–804 quiz e14–5.
105. 105 Del Chiaro, M., Verbeke, C.S., Kartalis, N., et al. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. JAMA Surg 150 (2015), 512–518.
106. 106 Axilbund, J.E., Brune, K.A., Canto, M.I., et al. Patient perspective on the value of genetic counselling for familial pancreas cancer. Hered Cancer Clin Pract 3 (2005), 115–122.
107. 107 Konings, I.C., Sidharta, G.N., Harinck, F., et al. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology, 2015 [Epuh ahead of print].
108. 108 Harinck, F., Nagtegaal, T., Kluijt, I., et al. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 13 (2011), 1015–1024.
109. 109 Maheu, C., Vodermaier, A., Rothenmund, H., et al. Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Fam Cancer 9 (2010), 617–624.
110. 110 Hart, S.L., Torbit, L.A., Crangle, C.J., et al. Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Psychooncology 21 (2012), 1324–1330.
111. 111 Underhill, M., Berry, D., Dalton, E., et al. Patient experiences living with pancreatic cancer risk. Hered Cancer Clin Pract, 13, 2015, 13.
112. 112 Lewis, Z.K., Frost, C.J., Venne, V.L., Pancreatic cancer surveillance among high-risk populations: knowledge and intent. J Genet Couns 18 (2009), 229–238.
113. 113 Breitkopf, C.R., Sinicrope, P.S., Rabe, K.G., et al. Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Hered Cancer Clin Pract, 10, 2012, 8.
114. 114 Jarvinen, H.J., Mecklin, J.P., Sistonen, P., Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108 (1995), 1405–1411.
115. 115 Jarvinen, H.J., Renkonen-Sinisalo, L., Aktan-Collan, K., et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27 (2009), 4793–4797.
116. 116 Dove-Edwin, I., Sasieni, P., Adams, J., et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ, 331, 2005, 1047.
117. 117 Engel, C., Rahner, N., Schulmann, K., et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8 (2010), 174–182.
118. 118 Stuckless, S., Green, J.S., Morgenstern, M., et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 82 (2012), 439–445.
119. 119 Vasen, H.F., Abdirahman, M., Brohet, R., et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138 (2010), 2300–2306.
120. 120 de Vos tot Nederveen Cappel, W.H., Nagengast, F.M., Griffioen, G., et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45 (2002), 1588–1594.
121. 121 Vasen, H.F., Moslein, G., Alonso, A., et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57 (2008), 704–713.
122. 122 Bjork, J.A., Akerbrant, H.I., Iselius, L.E., et al. Risk factors for rectal cancer morbidity and mortality in patients with familial adenomatous polyposis after colectomy and ileorectal anastomosis. Dis Colon Rectum 43 (2000), 1719–1725.
123. 123 Bulow, S., Results of national registration of familial adenomatous polyposis. Gut 52 (2003), 742–746.
124. 124 Heiskanen, I., Luostarinen, T., Jarvinen, H.J., Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 35 (2000), 1284–1287.
125. 125 da Luz Moreira, A., Church, J.M., Burke, C.A., The evolution of prophylactic colorectal surgery for familial adenomatous polyposis. Dis Colon Rectum 52 (2009), 1481–1486.
126. 126 Galiatsatos, P., Foulkes, W.D., Familial adenomatous polyposis. Am J Gastroenterol 101 (2006), 385–398.
127. 127 Bulow, S., Bjork, J., Christensen, I.J., et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 53 (2004), 381–386.
128. 128 Lopez-Ceron, M., van den Broek, F.J., Mathus-Vliegen, E.M., et al. The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. Gastrointest Endosc 77 (2013), 542–550.
129. 129 Bjork, J., Akerbrant, H., Iselius, L., et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 121 (2001), 1127–1135.
130. 130 Saurin, J.C., Gutknecht, C., Napoleon, B., et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22 (2004), 493–498.
131. 131 Herraiz, M., Barbesino, G., Faquin, W., et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5 (2007), 367–373.
132. 132 Attard, T.M., Giardiello, F.M., Argani, P., et al. Fundic gland polyposis with high-grade dysplasia in a child with attenuated familial adenomatous polyposis and familial gastric cancer. J Pediatr Gastroenterol Nutr 32 (2001), 215–218.
133. 133 Knudsen, A.L., Bisgaard, M.L., Bulow, S., Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2 (2003), 43–55.
134. 134 Nielsen, M., Morreau, H., Vasen, H.F., et al. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol 79 (2011), 1–16.
135. 135 Vogt, S., Jones, N., Christian, D., et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology, 137, 2009 1976–85.e1–10.
136. 136 Guarinos, C., Juarez, M., Egoavil, C., et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res 20 (2014), 1158–1168.
137. 137 Cleary, S.P., Cotterchio, M., Jenkins, M.A., et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136 (2009), 1251–1260.
138. 138 Landon, M., Ceulemans, S., Saraiya, D.S., et al. Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis. Clin Genet 87 (2015), 368–372.
139. 139 Beggs, A.D., Latchford, A.R., Vasen, H.F., et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59 (2010), 975–986.
140. 140 van Lier, M.G., Wagner, A., Mathus-Vliegen, E.M., et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. author reply 1265 Am J Gastroenterol 105 (2010), 1258–1264.
141. 141 Latchford, A.R., Neale, K., Phillips, R.K., et al. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum 55 (2012), 1038–1043.
142. 142 Howe, J.R., Haidle, J.L., Lal, G., et al. ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 71 (2007), 91–92.
143. 143 Chow, E., Macrae, F., A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 20 (2005), 1634–1640.
144. 144 Schreibman, I.R., Baker, M., Amos, C., et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 100 (2005), 476–490.
145. 145 Rijcken, F.E., Mourits, M.J., Kleibeuker, J.H., et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91 (2003), 74–80.
146. 146 Clendenning, M., Young, J.P., Walsh, M.D., et al. Germline Mutations in the Polyposis-Associated Genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 Are Not Common in Individuals with Serrated Polyposis Syndrome. PLoS One, 8, 2013, e66705.
147. 147 Rex, D.K., Ahnen, D.J., Baron, J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 107 (2012), 1315–1329 quiz 1314, 1330.
148. 148 Leach, M.O., Boggis, C.R., Dixon, A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (2005), 1769–1778.
149. 149 Axilbund, J.E., Wiley, E.A., Genetic testing by cancer site: pancreas. Cancer J 18 (2012), 350–354.
150. 150 Stoffel, E.M., Screening in GI Cancers: The Role of Genetics. J Clin Oncol 33 (2015), 1721–1728.